Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus

Diabetes Therapy

Volumn 5, Issue 1, 2014, Pages 169-181

  Odawara, Masato ^a   Hamada, Izumi ^b   Suzuki, Manabu ^b  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Antidiabetic drug; Dipeptidyl peptidase 4 inhibitor; Glycemic control; Metformin; Randomized trial; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; PLACEBO; VILDAGLIPTIN;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BODY MASS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GOOD CLINICAL PRACTICE; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS;

EID: 84925743102     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0059-x     Document Type: Article

References (26)

1. International Diabetes Federation. IDF Diabetes Atlas. 5th ed. Brussels, Belgium: International Diabetes Federation; 2011. http://www.idf.org/diabetesatlas/5e/diabetes. Accessed Aug 5, 2013.
2. Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev. 2002;18:S9–13.
3. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev. 2009;25:705–16.
4. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism. 2004;53:831–5.
5. Japan Diabetes Clinical Data Management Study Group. HbA1c (NGSP) in 2008. Ibaraki. http://jddm.jp/data/index.html. Accessed Aug 10, 2013.
6. Japan Diabetes Society, Treatment Guide for Diabetes edited by Japan Diabetes Society 2012–2013. Bunkodo Co. Ltd.; 2013.
7. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25–33.
8. Ahrén B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin’s action when added to metformin. Diabetes Obes Metab. 2011;13:193–203.
9. Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13:775–83.
10. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:132–8.
11. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890–5.
12. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10:1047–56.
13. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9:166–74.
14. Kothny W, Foley JE, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:252–7.
15. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83:233–40.
16. Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with Type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab. 2010;12:700–8.
17. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11:506–15.
18. Kadowaki T, Tajima N, Odawara M, Nishii M, Taniguchi T, Ferreira JCA. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. J Diabetes Investig. 2013;4:174–81.
19. Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab. 2012;14:927–36.
20. Inagaki N, Watada H, Murai M, et al. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:833–43.
21. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249–55.
22. Odawara M, Suzuki M, Hamada I, Iguchi A. Clinical evaluations of the vildagliptin combination therapy in type 2 diabetes patients – A long term safety study of 52 weeks treatment with vildagliptin as add-on therapy with metformin, TZD, α-GI or Glinides. J New Rem Clin. 2012;12:2593–611 (article in Japanese).
23. Matthews DR, Dejager S, Ahrén B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12:780–9.
24. Schweizer A, Dejager S, Foley JE, Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag. 2011;7:49–57.
25. Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;6:541–8.
26. Migoya EM, Bergeron R, Miller JL, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther. 2007;88:801–8.